ArvinasARVN
About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Employees: 445
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
546% more call options, than puts
Call options by funds: $6.61M | Put options by funds: $1.02M
68% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 53
3.41% more ownership
Funds ownership: 100.24% [Q1] → 103.65% (+3.41%) [Q2]
6% less funds holding
Funds holding: 219 [Q1] → 205 (-14) [Q2]
33% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 43
33% less capital invested
Capital invested by funds: $2.81B [Q1] → $1.89B (-$927M) [Q2]
36% less funds holding in top 10
Funds holding in top 10: 11 [Q1] → 7 (-4) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Andrew Fein 49% 1-year accuracy 62 / 126 met price target | 242%upside $87 | Buy Reiterated | 1 Aug 2024 |
Wedbush Robert Driscoll 53% 1-year accuracy 26 / 49 met price target | 124%upside $57 | Outperform Reiterated | 31 Jul 2024 |
Barclays Peter Lawson 46% 1-year accuracy 12 / 26 met price target | 89%upside $48 | Overweight Maintained | 31 Jul 2024 |
Oppenheimer Matthew Biegler 33% 1-year accuracy 8 / 24 met price target | 97%upside $50 | Outperform Maintained | 31 Jul 2024 |
